About Exact Sciences Corporation - Common Stock (EXAS)
Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions. With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management. Read More
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 20% year on year to $850.7 million. The company’s full-year revenue guidance of $3.23 billion at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was 49.4% above analysts’ consensus estimates.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 24–29, 2025, at the Phoenix Convention Center in Phoenix, Arizona. The company’s research showcases leadership in advancing colorectal cancer (CRC) screening through high-quality science, real-world evidence, and innovations that improve screening adherence and access across diverse patient populations. ACG abstracts are available on their website.
Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies” in the Journal of the National Cancer Institute.1 The modeling study found that Cologuard Plus™, a triennial next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guideline-recommended intervals and age ranges.1
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS)
jumped 2.2% in the afternoon session after the Nancy Gardner Sewell MCED Act advanced in the U.S. House, a development that could lead to Medicare coverage for multi-cancer early detection tests.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal cancer—the nation’s second leading cause of cancer-related death.1
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.
